Journal of Clinical Case Reports and Images

Current Issue Volume No: 1 Issue No: 4

ISSN: 2641-5518
share this page

Case Report Open Access
  • Available online freely Peer Reviewed
  • Sustained Clinical Response of Pseudotumoral Lesion of the Central Nervous System in Behcet's Disease After Treatment with Infliximab. Case Report.

    Joseph Bruno Bidin Brooks 1   Fábio César Prosdócimi 2   Rodrigo André Oliveira 3   Guilherme Lopes da Silveira 4  

    1Joseph Bruno Bidin Brooks- Department of Structure and Function, UNIMES- Universidade Metropolitana de Santos, São Paulo, Brazil

    2Fábio César Prosdócimi- Department of Structure and Function, UNIMES- Universidade Metropolitana de Santos, São Paulo, Brazil

    3Rodrigo André Oliveira- Clínica MegaImagem- Santos, São Paulo, Brazil

    4Guilherme Lopes da Silveira- Clínica MegaImagem- Santos, São Paulo, Brazil

    Author Contributions
    Received 06 Jan 2020; Accepted 15 Feb 2020; Published 17 Feb 2020;

    Academic Editor: Mona Hassan, Department of Human Anatomy and Embryology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.

    Checked for plagiarism: Yes

    Review by: Single-blind

    Copyright ©  2020 Joseph Bruno Bidin Brooks, et al.

    Creative Commons License     This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

    Competing interests

    The authors have declared that no competing interests exist.


    Joseph Bruno Bidin Brooks, Fábio César Prosdócimi, Rodrigo André Oliveira, Guilherme Lopes da Silveira (2020) Sustained Clinical Response of Pseudotumoral Lesion of the Central Nervous System in Behcet's Disease After Treatment with Infliximab. Case Report.. Journal of Clinical Case reports and Images - 1(4):20-22.

    Download as RIS, BibTeX, Text (Include abstract )

    DOI 10.14302/issn.2641-5518.jcci-20-3166


    Behcet's disease (BD) is a multisystem relapsing inflammatory immune-mediated disorder of unknown cause. The Central Nervous System can be affected involving parenchymal and/or vascular topography, such as brainstem, basal ganglia, thalamus, cortex and white matter, spinal cord and cranial nerves.Peripheral nervous system involvement is rare. The neurologic presentations are uncommon, around 10% of historical cases, may present as a primary manifestation or in systemic involvement and more prevalent in younger male patients. Neurobehcet is also associated with abnormalities in complementary exams, like in imaging studies, laboratory and cerebrospinal fluid analysis. 1, 2, 3, 4, 5


    The report of this case was submitted and approved by local ethics committee.

    Case Presentation

    The present case refers to a 49-year-old caucasian woman admitted to local hospital with a 3-month history of progressive holocranial headache, gait instability and diplopia. Her medical history included recurrent oral and genital ulcers, uveitis and erythema nodosum in both legs. Presence of a pathergy phenomenon and HLA-B51 were confirmed. Hematological and serum biochemistry tests were within normal-range values.

    Family medical background was unremarkable. Brain T2-FLAIR magnetic resonance imaging (MRI) showed an expansive mass lesion at the left capsular nucleus region, with mesencephalic extension (Figure 1A). Cerebrospinal fluid analyses showed 15 cells, all of them lympho-monocytes, and protein of 45mg/dL (lumbar puncture). All other tests on spinal fluid were normal.

    The patient was also referred to a neurosurgery department, where a brain biopsy was planned for diagnostic clarification. Meanwhile, the possible clinical diagnosis of BD was postulated and started treatment with 1 gram of methylprednisolone intravenously and for a period of 5 days with satisfactory results. Neurosurgery was then discarded. Therapeutic follow-up was instituted with azathioprine and after 2 months of treatment, due to abnormal liver function, anti-TNF-alpha (Infliximab) was was administered at 0, 2nd and 6th weeks and then every eight weeks; Despite cerebral atrophy, stable neurological evolution was found after 18 months of anti-TNF-alpha therapy (Figure 1B).

    Figure 1. Brain Axial-FLAIR-MRI- (A) Expansive mass lesion with hyperintense signal in the left capsular nucleus region, with mesencephalic extension and enhancement by the paramagnetic agent (white arrows). (B) Complete improvement of the expansive mass lesion with the presence of brain atrophy.
    Figure 1.


    Neurological involvement occurs in approximately 10% of BD patients and is characterized by an interval of 5 years since the onset of systemic and the neurological symptoms. Clinical and neuroimaging findings suggest parenchymal and extra-parenchymal inflammatory involvement. Pseudotumoral lesion of the Central Nervous System demonstrates inflammatory activity; Brain atrophy can coexist since the beginning of the inflammatory course and demonstrates neurodegeneration. 6 We reported a patient with BD associated with a pseudotumoral lesion of the Central Nervous System, a rare neurological involvement. The patient presented adverse effect to conventional immunosuppressive treatment, with azathioprine and had sustained clinical response with infliximab.

    The present case highlights the difficulties in diagnosing BD, which may leave incorrect diagnosis and therapeutic delay.


    1.H U Behcet. (1937) ber residivierende, aphto¨se durch ein Virus verursachtes Geschwu¨re am Mund, am Auge und an der Genitalien. Derm Wschr;. 105, 1152-1157.
    2. (1990) International StudyGroup for BehcetsDisease. Criteria for diagnosis of Behcets disease. Lancet;335: 1078-1080.
    3.Akman-Demir G, Serdaroglu P, Tasci B. (1999) Clinical patterns of neurological involvement in Behcets disease: evaluation of 200 patients. , The Neuro-Behcet Study Group. Brain; 122, 2171-2182.
    4.Borhani-Haghighi A, Kardeh B, Banerjee S, Yadollahikhales G. (2019) Neuro-Behcet's disease: An update on diagnosis, differential diagnoses, and treatment. Mult Scler Relat Disord;. 23(39), 101906.
    5.Toledo-Samaniego N, Galeano-Valle F, Ascanio-Palomares P. (2020) . Neurological manifestations of Behçet's disease: Study of 57 patients.Med Clin (Barc);19: 30713-4.
    6.Siva A, Saip S. (2009) The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis. , J 256(4), 513-29.